Favorable event free-survival of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for higher risk diffuse large B-cell lymphoma in first complete remission

7Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been applied to patients with diffuse large Bcell lymphoma (DLBCL); it is well established that ASCT shows significant survival benefits for chemosensitive relapse. However, half of relapsed patients are resistant to salvage chemotherapy, indicating that they are not suitable for ASCT. We retrospectively analyzed the clinical records of 47 patients with DLBCL classified as high or high-intermediate (higher) risk, according to the International Prognostic Index, who underwent upfront ASCT in first complete remission (CR1). Compared with 10 patients with similar characteristics who did not receive ASCT, event free survival at 5-year was significantly superior in ASCT group. Toxicity of ASCT was acceptable and therapy-related death was not observed. We therefore propose that upfront ASCT for higher risk DLBCL in CR1 might provide survival benefit, probably because the high-dose therapy removes minimally resided tumor.

Cite

CITATION STYLE

APA

Kaneko, H., Tsutsumi, Y., Fujino, T., Kuwahara, S., Ohshiro, M., Iwai, T., … Taniwaki, M. (2015). Favorable event free-survival of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for higher risk diffuse large B-cell lymphoma in first complete remission. Hematology Reports, 7(2), 44–47. https://doi.org/10.4081/hr.2015.5812

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free